{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of confidence interval was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"16.2","upperLimit":"NA","value":"26.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"OS was defined as the time from brexucabtagene autoleucel infusion to the date of death from any cause. Participants who had not died by the analysis data cutoff date were censored at their last contact date. KM estimates was used for analyses.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \\> 100 kg, a maximum flat dose of 1 x 10\\^8 anti-CD19 CAR T cells/kg of body weight was administered.","id":"OG000","title":"Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg"}],"paramType":"MEDIAN","populationDescription":"Participants in mITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"First infusion date of brexucabtagene autoleucel (Phase 2) up to 5 years","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}